Micreos Pharmaceuticals Partners With Biologics CDMO Northway Biotech for Its Engineered Endolysin Therapeutic Manufacturing Program
ZUG, SWITZERLAND AND VILNIUS, LITHUANIA / / March 4, 2025 / Micreos Pharmaceuticals AG ("Micreos"), a preclinical-stage biopharmaceutical company, specializing in developing Engineered Endolysin therapies to target harmful pathogens that cause disease aggravation, has entered into a strategic partnership with Northway Biotech ("NBT"), a Contract Development and Manufacturing Organization (CDMO) to develop scalable cGMP production processes for Micreos' biologic therapeutic MEndoB, which is the first-in-class dual-active domain targeted medicine that will enter the clinic in the coming months as an investigational therapeutic to treat Atopic Dermatitis.
Micreos is focused on developing best-in-class targeted therapeutics to precisely target harmful pathogens that cause disease flares to help address significant unmet medical needs in dermatology and oncology.
As part of the partnership, Northway Biotech will apply its significant expertise in biologics manufacturing to develop a scalable GMP production process for Micreos' engineered endolysin technology. The collaboration will also include developing and validating robust analytical methods, cell bank manufacturing, technology scale-up for cGMP Drug Substance generation, and IND/IMPD supporting documentation preparation, to ensure that the production of Micreos' engineered endolysins complies with stringent regulatory standards for clinical trials.
Matt Regan, CEO of Micreos, stated: "This partnership with Northway Biotech marks a significant milestone for Micreos as we advance our engineered endolysins into scalable therapeutics for clinical trials. By developing targeted medicines that address the underlying pathophysiology associated with disease aggravation in conditions such as atopic dermatitis and cutaneous T-Cell lymphoma, and by leveraging Northway's significant manufacturing expertise, we are poised to make a meaningful impact on patient care in areas of great unmet medical need."
Prof. Vladas Algirdas Bumelis, CEO and Chairman of Northway Biotech, highlighted the mutual commitment to high-quality manufacturing: "We are honored to contribute to Micreos' innovative engineered endolysin therapies. With a dedicated and highly experienced team in recombinant protein process development and scale-up, we aim to accelerate Micreos' development by providing cGMP drug substance material available by the end of summer 2024."
André Markmann, PhD, VP of Business Development at Northway Biotech, added: "Micreos' engineered endolysins address critical healthcare challenges. We are excited to support Micreos in advancing their breakthrough therapy into clinical trials at a rapid pace while ensuring the highest standards."
About MEndoB
Micreos' MEndoB is the first-in-class and potentially best-in-class dual-active domain, targeted medicine designed for optimum activity on human skin. It works through targeted enzymatic degradation of the targets cell wall, rapidly killing the harmful pathogen, but without triggering drug resistance or having any off target affects. Micreos' engineering expertise has enhanced drug stability and activity but has also been validated to effectively penetrate biofilms, eliminate dormant & hard to kill pathogenic cells, and potentially deliver synergies with other medications. With demonstrated preclinical efficacy, MEndoB holds significant promise for treating chronic and difficult-to-treat conditions in dermatology and oncology.
About Micreos
Micreos is a preclinical-stage biopharmaceutical company developing highly innovative, targeted therapies as a new way to treat chronic conditions in dermatology and oncology where there is a high unmet medical need. With its advanced engineering platform, Micreos is developing targeted medicines that selectively eliminate harmful pathogens while preserving the beneficial microbiome, paving the way for future indications in dermatology, oncology, and beyond.
For more information, visit www.micreos.com.
About Northway Biotech
Northway Biotech is a leading contract development and manufacturing organization (CDMO) supporting customers worldwide. Its highly experienced and professional team executes projects at every stage, from cell line construction and process development to cGMP manufacturing of biopharmaceutical products. The company's extensive expertise and vertically integrated service offering enables rapid execution of multiple projects from its state-of-the-art GMP facilities while ensuring full process and product compliance at all stages of research, development, and commercial manufacturing. Northway Biotech is a privately owned company founded in 2004 and operates locations in Vilnius, Lithuania; London, United Kingdom; and Waltham, MA, USA.
For more information, please visit www.northwaybiotech.com.
Micreos Contact:
Matt ReganCEO and Board member, Micreos Pharmaceutical AGm.regan@micreos.com
Northway Biotech Contact:
Vladas Algirdas BumelisCEO and Chairman of the Boardvladas.bumelis@northwaybiotech.com
Contact Information
Vladas Bumelis CEO and Chairman of the Boardvladas.bumelis@northwaybiotech.com
SOURCE: Northway Biotech
View the original press release on ACCESS Newswire
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
a day ago
- Yahoo
Addex to Present Positive GABAB PAM Chronic Cough Data at the 10th American Cough Conference
Geneva, Switzerland, June 5, 2025 - Addex Therapeutics (SIX/NASDAQ: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, announced today that preclinical data from its gamma-aminobutyric acid sub-type B receptor (GABAB) positive allosteric modulator (PAM) cough program will be presented at the 10th American Cough Conference (June 6-7) in Dulles, VA. A presentation given by Mikhail Kalinichev, Head of Translational Science at Addex will describe the progress seen to date with the Addex GABAB PAM cough program, including antitussive data from in vivo models. Addex lead drug candidate is ready to start IND enabling studies. Details of the Presentation Date: Saturday, June 7, 2025Time: 11:20 am ESTTitle: Compound A, a novel positive allosteric modulator of the GABAB receptor, shows robust antitussive efficacy and signs of wide therapeutic margin in models of cough in guinea pigsLocation: Hyatt Regency Dulles, 2300 Dulles Corner Blvd., Herndon, VA, US, 20171 About GABAB activation and cough:The main inhibitory neurotransmitter GABA activates ionotropic (GABAA) and metabotropic (GABAB) types of receptors. GABAB receptors are widely expressed on airways and in the central and peripheral components of the cough neural circuit. Activating GABAB receptors to treat chronic cough has been clinically validated with baclofen, a selective GABAB agonist, that binds the receptor within the orthosteric GABA binding site. Baclofen is used off-label to treat chronic cough patients, but its wider use is limited due to serious side effects, short half-life and gradual loss of efficacy during chronic treatment. Targeting an allosteric site of the receptor is expected to provide many advantages, including higher selectivity, better tolerability and lack of tolerance compared to an orthosteric compound. About Addex TherapeuticsAddex is a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders. Addex's lead drug candidate, dipraglurant (mGlu5 negative allosteric modulator or NAM), is under evaluation for future development in brain injury recovery, including post-stroke and traumatic brain injury recovery. Addex's partner, Indivior, has selected a GABAB PAM drug candidate for development in substance use disorders and has successfully completed IND enabling studies. Addex is advancing an independent GABAB PAM program for chronic cough. Addex also holds a 20% equity interest in a private spin out company, Neurosterix LLC, which is advancing a portfolio of allosteric modulator programs, including M4 PAM for schizophrenia, mGlu7 NAM for mood disorders and mGlu2 NAM for mild neurocognitive disorders. Addex shares are listed on the SIX Swiss Exchange and American Depositary Shares representing its shares are listed on the NASDAQ Capital Market, and trade under the ticker symbol 'ADXN' on each exchange. For more information, visit Contacts: Tim Dyer Chief Executive Officer Telephone: +41 22 884 15 55 PR@ Mike Sinclair Partner, Halsin Partners +44 (0)7968 022075 msinclair@ Addex Forward Looking Statements:This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements about the intended use of proceeds of the offering. The words 'may,' 'will,' 'could,' 'would,' 'should,' 'expect,' 'plan,' 'anticipate,' 'intend,' 'believe,' 'estimate,' 'predict,' 'project,' 'potential,' 'continue,' 'target' and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release, are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, uncertainties related to market conditions. These and other risks and uncertainties are described in greater detail in the section entitled 'Risk Factors' in Addex Therapeutics' Annual Report on Form 20-F, prospectus and other filings that Addex Therapeutics may make with the SEC in the future. Any forward-looking statements contained in this press release represent Addex Therapeutics' views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. Addex Therapeutics explicitly disclaims any obligation to update any forward-looking statements. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Fox News
a day ago
- Fox News
Woman charged after overdose death of man whose body was found in Planet Fitness tanning bed
Police in Indiana have arrested a woman for her alleged role in the overdose death of a 39-year-old man whose body was found inside a tanning bed three days after he entered a Planet Fitness gym. The Indianapolis Metropolitan Police Department (IMPD) said in a news release that Heather Bradford, 41, was arrested and charged with dealing a controlled substance resulting in death, narcotics possession and for having two active warrants in Morgan County, Indiana. Police responded to Planet Fitness just before 8:30 a.m. Nov. 11 after receiving a report that a body had been discovered in the gym. The Marion County Coroner's Office identified the man as Derek Sink. According to police records obtained by 13 News, Sink's family last had contact with him Nov. 8 and reported him missing Nov. 10. MAN FOUND DEAD IN TANNING BED AT PLANET FITNESS IN INDIANAPOLIS 3 DAYS AFTER HE WALKED INTO THE GYM Sink was pronounced dead at the gym, police said Tuesday, and the coroner's office determined his cause of death to be a drug overdose. The IMPD Overdose Death Task Force (ODTF) took over the case, and, through a variety of investigative techniques, detectives identified Bradford as a suspect in Sink's death. YOUNG AMERICAN TOURISTS FOUND DEAD AT CARIBBEAN BEACH RESORT; AUTHORITIES INVESTIGATING The next day, Bradford was located at a gas station in Mooresville, Indiana, where she was taken into custody without incident by ODTF Investigators along with Indiana State Police and members of the Drug Enforcement Administration (DEA). "These are extremely challenging and emotionally heavy investigations, but they are vital in our effort to combat the ongoing overdose epidemic," IMPD Chief Chris Bailey said. "Each arrest represents months of work, cross-agency coordination, and a deep commitment to seeking justice for families who've lost loved ones." ARKANSAS NURSE CHARGED WITH USING DEAD PATIENT'S NAME IN ATTEMPT TO PURCHASE HUNDREDS OF OXYCODONE PILLS Planet Fitness released a statement after Sink's body was discovered in one of its gyms. CLICK HERE TO GET THE FOX NEWS APP "At Planet Fitness, we have robust operational brand protocols in place, as the safety and well-being of our members is our top priority," McCall Gosselin, chief corporate affairs officer at Planet Fitness, said in a statement. "We are working closely with our local franchisee to ensure they are upholding those brand protocols." Gosselin added that the franchise owner was working with local authorities in the investigation. Fox News Digital's Stepheny Price contributed to this report.
Yahoo
a day ago
- Yahoo
Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (BPTH) Q1 25
Dallas, Texas--(Newsfile Corp. - June 4, 2025) - Bio-Path Holdings, Inc. (OTCQB: BPTH): Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (OTCQB: BPTH) for Q1 2025. Bio-Path Holdings, Inc. (OTCQB: BPTH) is a clinical-stage biotechnology company based in Bellaire, Texas, pioneering RNA interference (RNAi) therapeutics through its proprietary DNAbilize® platform. This innovative technology employs neutral-charge, liposomal delivery of antisense oligonucleotides, enhancing drug stability and cellular uptake while minimizing toxicity. The Company's lead candidate, prexigebersen (BP1001), targets the Grb2 protein and is currently in Phase 2 trials for acute myeloid leukemia (AML). A modified version, BP1001-A, is undergoing Phase 1/1b trials for solid tumors and has shown promise in preclinical studies for obesity and type 2 diabetes. Another candidate, BP1002, targets the Bcl-2 protein and is being evaluated for blood cancers and solid tumors. Bio-Path is also preparing an Investigational New Drug (IND) application for BP1003, a STAT3 inhibitor aimed at treating pancreatic cancer. To view the full announcement, including downloadable images, bios, and more, click here. Key Takeaways: Phase 2 prexigebersen data shows potential for FDA approval in AML treatment. BP1001-A trial shows early signs of efficacy in advanced solid tumors. Advancing pipeline backed by strategic R&D and a robust patent portfolio. Click image above to view full announcement. About StonegateStonegate Capital Partners is a leading capital markets advisory firm providing investor relations, equity research, and institutional investor outreach services for public companies. Our affiliate, Stonegate Capital Markets (member FINRA), provides a full spectrum of investment banking services for public and private companies. Contacts: Stonegate Capital Partners (214) 987-4121 info@ Source: Stonegate, Inc. To view the source version of this press release, please visit
